Corticosteroids, An Issue of Rheumatic Disease Clinics of North America
1. Auflage
Erschienen am 19. Januar 2016
100 Seiten
978-0-323-41713-6 (ISBN)
Beschreibung
Corticosteroids represent the most important and frequently used class of anti-inflammatory and immunosuppressant agents in the management of many rheumatological conditions. Included in this issue will be articles on the following topics: Glucocorticoid use in intra-articular and soft tissue injections, corticosteroids and osteoporosis, corticosteroids in lupus, ANCA associated vasculitis, and many more!
Weitere Details
Weitere Ausgaben
Andere Ausgaben
Marcy B. Bolster
Corticosteroids, An Issue of Rheumatic Disease Clinics of North America: Volume 42-1
Buch
12/2015
Elsevier
79,18 €
Versand in 15-20 Tagen
Inhalt
- Front Cover
- Corticosteroids
- Copyright
- Contributors
- CONSULTING EDITOR
- EDITOR
- AUTHORS
- Contents
- Foreword: Corticosteroids
- Preface: Corticosteroids: Friends and Foes
- The History of Cortisone Discovery and Development
- Corticosteroids: Mechanisms of Action in Health and Disease
- Glucocorticoids and Rheumatoid Arthritis
- Corticosteroids in Lupus
- Corticosteroids in Lupus Nephritis and Central Nervous System Lupus
- Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis
- Corticosteroids in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
- Corticosteroids in Myositis and Scleroderma
- Corticosteroids in Sarcoidosis
- Corticosteroids for Pain of Spinal Origin: Epidural and Intraarticular Administration
- Infection Risk and Safety of Corticosteroid Use
- Glucocorticoid-induced Osteoporosis
- RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- FORTHCOMING ISSUES
- May 2016
- August 2016
- November 2016
- RECENT ISSUES
- November 2015
- August 2015
- May 2015
- Foreword: Corticosteroids
- Preface: Corticosteroids: Friends and Foes
- The History of Cortisone Discovery and Development
- Key points
- INTRODUCTION
- PHILIP SHOWALTER HENCH
- EDWARD CHARLES KENDALL
- WORLD WAR II
- MRS G
- THE STORY BREAKS
- THE NOBEL PRIZE
- AFTERMATH
- THE EMPIRE STRIKES BACK
- EPILOGUE
- THE LEGACY OF CORTICOSTEROIDS
- REFERENCES
- Corticosteroids
- Key points
- INTRODUCTION
- GLUCOCORTICOID SYNTHESIS, SECRETION, AND BIOAVAILABILITY
- GLUCOCORTICOID RECEPTOR
- MECHANISMS OF GLUCOCORTICOID ACTION
- Genomic Actions of Glucocorticoids
- Nongenomic Actions of Glucocorticoids
- GLUCOCORTICOID RECEPTOR HETEROGENEITY
- Glucocorticoid Receptor Splice Variants
- Glucocorticoid Receptor Translational Isoforms
- Posttranslational Modifications of Glucocorticoid Receptor
- Glucocorticoid Receptor Polymorphisms
- SUMMARY AND FUTURE CONSIDERATIONS
- REFERENCES
- Glucocorticoids and Rheumatoid Arthritis
- Key points
- INTRODUCTION
- CLINICAL APPLICATIONS IN RHEUMATOID ARTHRITIS
- Inflammation Under Control
- Pain Relief and Structural Progression
- Fatigue, Anxiety, and Depression
- DOSING IN RHEUMATOID ARTHRITIS
- Equivalents of Prednisone
- ADMINISTRATION IN RHEUMATOID ARTHRITIS
- Systemic
- Oral
- Parenteral
- Intra-articular
- SIDE EFFECTS
- Patient Education
- Minimizing glucocorticoid side effects
- Osteoporosis and Fractures
- Other Musculoskeletal Adverse Events
- Endocrine and Metabolic Adverse Events
- Glucose metabolism and diabetes
- Weight gain
- Hypothalamic-pituitary-adrenal axis suppression
- Cardiovascular Risk Factors and Atherosclerosis
- Infections
- Renal Dysfunction
- Dermatologic Side Effects
- Ophthalmologic Side Effects
- Gastrointestinal Side Effects
- Neuropsychological Side Effects
- DRUG-DRUG INTERACTIONS
- FUTURE CONSIDERATIONS
- SUMMARY
- REFERENCES
- Corticosteroids in Lupus
- Key points
- INTRODUCTION
- CLINICAL APPLICATIONS
- General
- Mucocutaneous
- Musculoskeletal
- Hematologic
- Cardiac
- Pulmonary
- Gastrointestinal
- Ophthalmologic
- Nephritis and Neuropsychiatric
- Pregnancy and Lactation
- DOSING
- Systemic Lupus Erythematosus Pathogenesis
- Mechanism of Corticosteroids
- Dosing
- Resistance to Corticosteroids
- ADMINISTRATION
- SIDE EFFECTS
- Corticosteroids and Damage
- Corticosteroids and Cardiovascular Disease
- Corticosteroids and Infections
- Corticosteroids and Fracture
- DRUG-DRUG INTERACTIONS
- PRACTICAL TREATMENT CONSIDERATIONS
- FUTURE CONSIDERATIONS/SUMMARY
- REFERENCES
- Corticosteroids in Lupus Nephritis and Central Nervous System Lupus
- Key points
- INTRODUCTION
- EPIDEMIOLOGY OF LUPUS NEPHRITIS
- EVALUATION OF LUPUS NEPHRITIS
- TREATMENT GOALS FOR LUPUS NEPHRITIS
- PROLIFERATIVE LUPUS NEPHRITIS INDUCTION THERAPY
- PROLIFERATIVE LUPUS NEPHRITIS MAINTENANCE THERAPY
- CHALLENGING CURRENT CORTICOSTEROID PRACTICES
- TAPERING OF CORTICOSTEROIDS
- EPIDEMIOLOGY OF CENTRAL NERVOUS SYSTEM LUPUS
- EVALUATION OF CENTRAL NERVOUS SYSTEM LUPUS
- COMMON CENTRAL NERVOUS SYSTEM FEATURES IN PATIENTS WITH LUPUS
- FEATURES OF LESS FREQUENT CENTRAL NERVOUS SYSTEM LUPUS EVENTS
- TREATMENT STRATEGIES FOR CENTRAL NERVOUS SYSTEM LUPUS
- IMMUNOSUPPRESSION FOR CENTRAL NERVOUS SYSTEM LUPUS REFRACTORY TO CORTICOSTEROIDS
- ADVERSE EFFECTS OF CORTICOSTEROIDS
- SUMMARY
- REFERENCES
- Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis
- Key points
- INTRODUCTION
- CLINICAL FEATURES
- MANAGEMENT
- GLUCOCORTICOIDS FOR TREATMENT OF POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
- MECHANISMS OF GLUCOCORTICOID ACTIONS
- WHY DOES CLINICAL EFFICACY OF GLUCOCORTICOID THERAPY VARY AMONG DIFFERENT PATIENTS?
- ADVERSE EFFECTS OF GLUCOCORTICOIDS
- CLINICAL ASPECTS OF THERAPY WITH GLUCOCORTICOIDS IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
- Polymyalgia Rheumatica
- Giant Cell Arteritis
- NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND ANALGESICS IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
- GLUCOCORTICOID-SPARING AGENTS IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
- Nonbiological Agents
- Biological Agents
- ASPIRIN USE IN GIANT CELL ARTERITIS
- MANAGEMENT OF GLUCOCORTICOID-RELATED COMPLICATIONS IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS
- SUMMARY
- REFERENCES
- Corticosteroids in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
- Key points
- INTRODUCTION
- REMISSION INDUCTION THERAPY
- Intravenous Glucocorticoids
- Oral Glucocorticoids
- MAINTENANCE THERAPY
- TREATMENT OF RELAPSES
- LOCAL GLUCOCORTICOIDS
- FUTURE CONSIDERATIONS
- SUMMARY
- REFERENCES
- Corticosteroids in Myositis and Scleroderma
- Key points
- IDIOPATHIC INFLAMMATORY MYOPATHIES
- Background and Clinical Manifestations
- Diagnostic Evaluation
- Classification Criteria for Idiopathic Inflammatory Myopathy
- Treatment Options
- POLYMYOSITIS
- Background and Clinical Manifestations
- Diagnostic Evaluation
- Treatment
- Corticosteroids
- Corticosteroid-sparing options
- DERMATOMYOSITIS
- Background and Clinical Manifestations
- Diagnostic Evaluation
- Treatment
- Corticosteroids
- Corticosteroid-sparing options
- INCLUSION BODY MYOSITIS
- Background and Clinical Manifestations
- Diagnostic Evaluation
- Treatment
- Corticosteroids
- Corticosteroid-sparing options
- NECROTIZING MYOPATHIES
- Background and Clinical Presentation
- Diagnostic Evaluation
- Treatment
- Corticosteroids
- Corticosteroid-sparing options
- SCLERODERMA: LOCALIZED SCLERODERMA (MORPHEA) AND SYSTEMIC SCLEROSIS
- LOCALIZED SCLERODERMA (MORPHEA)
- Background and Clinical Manifestations
- Diagnostic Evaluation
- Treatment
- Corticosteroids
- Corticosteroid-sparing options
- SYSTEMIC SCLEROSIS
- Background and Clinical Presentation
- Diagnostic Evaluation
- Treatment
- Skin
- Corticosteroids
- Corticosteroid-sparing options
- Musculoskeletal
- Corticosteroids
- Corticosteroid-sparing options
- Interstitial lung disease
- Corticosteroids
- Corticosteroid-sparing options
- Scleroderma renal crisis
- SUMMARY
- REFERENCES
- Corticosteroids in Sarcoidosis
- Key points
- INTRODUCTION
- INDICATIONS TO TREAT SARCOIDOSIS
- GENERAL APPROACH TO THE TREATMENT OF SARCOIDOSIS WITH CORTICOSTEROIDS
- Issues of Dose
- Issues of Duration
- Issues of When to Add Additional Agents to Corticosteroids
- CORTICOSTEROID THERAPY FOR SPECIFIC FORMS OF SARCOIDOSIS
- Pulmonary Sarcoidosis
- Cardiac Sarcoidosis
- Skin Sarcoidosis
- Eye Sarcoidosis
- Neurologic
- Musculoskeletal Involvement
- Other Organs
- SUMMARY
- REFERENCES
- Corticosteroids for Pain of Spinal Origin
- Key points
- INTRODUCTION
- BACKGROUND
- THERAPEUTIC RATIONALE
- CLINICAL INDICATIONS
- ANATOMIC TARGETS FOR CORTICOSTEROID INJECTION
- EPIDURAL STEROID INJECTION
- Epidural Steroid Injection: Three Approaches
- Epidural Steroid Injection: Efficacy
- Epidural Steroid Injection: Dosage
- Epidural Steroid Injection: Fluoroscopy
- LOCAL INJECTION FOR CHRONIC LOW BACK PAIN SYNDROMES ATTRIBUTED TO THE LUMBAR FACET JOINTS
- SACROILIAC JOINT INJECTION
- Comment: Area of Overlap - Spinal Injections into Facet/Sacroiliac Joints Related to Discussion in Other Chapters About Int ...
- Complications
- SIDE EFFECTS OF THE STEROIDS
- Complications: Dosage
- Complications: Steroid Formulation
- Complications: Needle Placement
- ORAL STEROIDS
- Contraindications
- REFERENCES
- Infection Risk and Safety of Corticosteroid Use
- Key points
- INTRODUCTION
- INFECTION IN RHEUMATIC DISEASES AND CORTICOSTEROIDS
- RANDOMIZED CONTROLLED TRIALS
- OBSERVATIONAL STUDIES
- OPPORTUNISTIC INFECTIONS
- PNEUMOCYSTIS JIROVECI PNEUMONIA
- Herpes Zoster
- Strongyloidiasis
- Tuberculosis
- VACCINATION AND OTHER PREVENTION STRATEGIES
- Pneumocystis jiroveci Pneumonia
- Herpes Zoster
- Tuberculosis
- SUMMARY
- REFERENCES
- Glucocorticoid-induced Osteoporosis
- Key points
- INTRODUCTION
- GLUCOCORTICOID EFFECTS ON BONE
- EPIDEMIOLOGY
- DIAGNOSIS/IDENTIFYING PATIENTS AT RISK
- Bone Mineral Density Measurement
- FRAX
- Other Testing Strategies
- PREVENTION AND TREATMENT
- Lifestyle Measures and Assessment
- Calcium and Vitamin D
- Bisphosphonates
- Teriparatide
- Denosumab
- Raloxifene
- Percutaneous Vertebroplasty
- International Guidelines for Glucocorticoid-induced Osteoporosis
- Postmenopausal women and men greater than or equal to 50 years of age
- Premenopausal women and men aged less than 50
- SUMMARY
- ACKNOWLEDGMENTS
- REFERENCES
- Index
